Drug intelligence / Profile preview

HG248

Development stage: Preclinical
Lead developer: HitGen
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

HG248 is a preclinical-stage small molecule PROTAC (Proteolysis Targeting Chimera) being developed by HitGen for the treatment of cancer. The drug candidate was discovered using HitGen's DNA-encoded chemical library (DEL) platform and utilizes targeted protein degradation (TPD) technology to eliminate specific disease-causing proteins. As of 2024, HG248 is in the lead optimization stage of development. While the specific molecular target has not been publicly disclosed, the compound represents HitGen's internal pipeline expansion into the TPD space.

Beyond the preview

Go deeper on HG248.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HG248.

Explore the full profile